Cancer Care Ontario | Cancer Care Ontario

304 Results

Guidelines and Advice

Ontario Health (Cancer Care Ontario) Endorsement of ASCO Rapid Recommendation on 177Lutetium-Prostate-Specific Membrane Antigen-617 (PSMA-617) for Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Status: Current
ID: GL-END 3-25

Nov 2023

Guidelines and Advice

Status: Current
ID: PET 2023-1

Nov 2023

Regimen

Cancer Type:

Hematologic,

Multiple Myeloma

Show More Show more tags

Intent: Palliative

Funding:

New Drug Funding Program

Bortezomib - In Combination with Lenalidomide and Dexamethasone for Previously Untreated Multiple Myeloma Pre-SCT

ODB Limited Use

lenalidomide - Induction therapy for transplant eligible, newly diagnosed multiple myeloma, according to clinical criteria

ODB - General Benefit

dexamethasone

Drugs Used:

Quick Link(s):

Dec 2023

Guidelines and Advice

Status: Current
ID: 8-7
Version: 2

Mar 2023